---
ver: rpa2
title: Generating crossmodal gene expression from cancer histopathology improves multimodal
  AI predictions
arxiv_id: '2502.00568'
source_url: https://arxiv.org/abs/2502.00568
tags:
- data
- transcriptomic
- synthesized
- risk
- survival
- transformers
- self-attention
- retrieval-augmented-generation
- instruction-tuning
- parameter-efficient-finetuning
- mixture-of-experts
- chain-of-thought
core_contribution: This paper introduces PathGen, a diffusion-based generative AI
  model that synthesizes transcriptomic data from digital histopathology whole slide
  images (WSIs). The model is trained and evaluated on four cancer cohorts from TCGA
  and CPTAC datasets (glioblastoma-glioma, renal, uterine, and breast).
---

# Generating crossmodal gene expression from cancer histopathology improves multimodal AI predictions

## Quick Facts
- arXiv ID: 2502.00568
- Source URL: https://arxiv.org/abs/2502.00568
- Authors: Samiran Dey; Christopher R. S. Banerji; Partha Basuchowdhuri; Sanjoy K. Saha; Deepak Parashar; Tapabrata Chakraborti
- Reference count: 40
- Primary result: PathGen synthesizes transcriptomic data from histopathology images with Spearman correlation 0.436-0.717 and improves cancer grading/survival prediction AUC and C-index scores

## Executive Summary
PathGen is a diffusion-based generative AI model that synthesizes transcriptomic data from digital histopathology whole slide images (WSIs). The model is trained and evaluated on four cancer cohorts from TCGA and CPTAC datasets, demonstrating strong correlation between synthesized and real transcriptomic data (Spearman correlation 0.436-0.717) with low normalized mean absolute error (0.141-0.178). When combined with WSIs for cancer grading and survival risk estimation, the synthesized transcriptomic features significantly improve predictive performance compared to WSIs alone, achieving state-of-the-art results. Critically, performance using synthesized transcriptomic data is statistically indistinguishable from using real transcriptomic data across all cohorts.

## Method Summary
PathGen employs a diffusion-based generative model architecture to synthesize transcriptomic features from histopathology whole slide images. The model processes WSIs through patch embeddings, aggregates them with case-level transcriptomic labels, and generates corresponding gene expression profiles. It is trained on four cancer cohorts from TCGA and CPTAC datasets, synthesizing six broad gene categories including cell cycle and immune response. The generated transcriptomic features are then integrated with WSIs for multimodal cancer grading and survival prediction tasks. The model provides clinical interpretability through co-attention maps and conformal prediction for uncertainty quantification, demonstrating fairness across patient demographics.

## Key Results
- Synthesized transcriptomic data shows Spearman correlation 0.436-0.717 with real data across cancer cohorts
- Normalized mean absolute error of synthesized data is 0.141-0.178
- Synthesized transcriptomic features significantly improve cancer grading and survival prediction (p-value <0.05) compared to WSIs alone
- Performance using synthesized transcriptomic data is statistically indistinguishable from real transcriptomic data (p-value >0.05)

## Why This Works (Mechanism)
The model leverages the rich molecular information embedded in histopathology images to generate corresponding transcriptomic profiles. By training on paired WSI-transcriptomic data, PathGen learns the cross-modal relationship between tissue morphology and gene expression patterns. The diffusion model architecture enables generation of high-fidelity synthetic transcriptomic features that capture biological patterns while maintaining statistical properties similar to real data. The co-attention mechanism provides interpretability by highlighting relevant image regions for gene expression synthesis.

## Foundational Learning
- **Diffusion models**: Why needed - Generate high-quality synthetic data by gradually denoising from random noise; Quick check - Verify the model follows the standard forward diffusion and reverse denoising process
- **Cross-modal learning**: Why needed - Establish relationships between histopathology images and transcriptomic data; Quick check - Confirm paired WSI-transcriptomic data exists for training
- **Gene category reduction**: Why needed - Reduce complexity from thousands of genes to six interpretable biological categories; Quick check - Verify the six categories cover major cancer-relevant pathways
- **Conformal prediction**: Why needed - Provide uncertainty quantification for clinical decision-making; Quick check - Confirm calibration curves show proper uncertainty estimates
- **Co-attention mechanisms**: Why needed - Enable interpretability by linking image regions to synthesized genes; Quick check - Verify attention maps highlight biologically relevant tissue features
- **Survival analysis metrics**: Why needed - Evaluate model performance for clinical endpoints; Quick check - Confirm C-index calculations follow established protocols

## Architecture Onboarding

**Component Map:**
WSI -> Patch Embeddings -> Case Aggregation -> Diffusion Model -> Synthesized Transcriptomics -> Multimodal Classifier -> Cancer Grading/Survival Prediction

**Critical Path:**
1. WSI patch extraction and embedding generation
2. Case-level transcriptomic data aggregation
3. Diffusion model training for gene synthesis
4. Integration of synthesized transcriptomics with WSIs
5. Multimodal classification for clinical endpoints

**Design Tradeoffs:**
- Uses six gene categories instead of full transcriptome to balance complexity and interpretability
- Employs patch-level embeddings aggregated to case level rather than spatial transcriptomics
- Implements conformal prediction for uncertainty quantification despite computational overhead

**Failure Signatures:**
- Poor correlation between synthesized and real transcriptomics indicates model collapse
- Overfitting to specific cancer cohorts suggests limited generalizability
- Misaligned co-attention maps indicate failure in cross-modal learning
- Degradation in multimodal performance suggests ineffective feature integration

**3 First Experiments to Run:**
1. Validate correlation metrics between synthesized and real transcriptomic data on held-out test sets
2. Compare multimodal performance with and without synthesized transcriptomics across all cancer cohorts
3. Analyze co-attention map quality to ensure biologically meaningful feature attribution

## Open Questions the Paper Calls Out

### Open Question 1
- Question: Can PathGen be validated as a screening tool to guide targeted transcriptomic data collection and improve patient treatment response?
- Basis in paper: [explicit] The authors state that a "dedicated follow up study" including "patient response to treatment" is required to realize their vision of using PathGen as a cost-effective screening tool in the clinic.
- Why unresolved: The current study relies on retrospective datasets (TCGA, CPTAC) and statistical performance metrics rather than prospective clinical intervention or treatment outcome analysis.
- What evidence would resolve it: A prospective clinical trial demonstrating that PathGen-guided selection for transcriptomic testing correlates with improved treatment selection and patient survival.

### Open Question 2
- Question: To what extent does the synthesis of only six broad gene categories limit the model compared to the biological diversity of the full transcriptome?
- Basis in paper: [explicit] The authors note that the synthesized features "do not capture the full diversity of the transcriptome" and acknowledge there is "likely a limit to how much of the full transcriptome can be synthesized" solely from WSIs.
- Why unresolved: The diffusion model is currently trained to predict specific gene groups rather than whole-transcriptome data, leaving the information loss from this reduction undefined.
- What evidence would resolve it: Comparative analysis between model performance using the six-gene synthesis versus synthesis of whole-transcriptome data or less abundant gene sets.

### Open Question 3
- Question: How can spatial transcriptomics data be integrated to improve the resolution and feature count of synthesized transcriptomics?
- Basis in paper: [explicit] The authors suggest that "spatial transcriptomics will provide insight" into the limits of synthesis and guide the development of "synthesized transcriptomic data with a greater number of features."
- Why unresolved: The current model aggregates transcriptomic data at the patient/case level and relies on patch embeddings, whereas spatial transcriptomics offers ground truth at the patch level which is currently unused.
- What evidence would resolve it: Experiments utilizing spatial transcriptomics ground truth to train PathGen, resulting in increased accuracy for a wider array of gene features.

## Limitations
- Performance improvements show considerable variation across cancer types, with uterine cancer showing the lowest correlation metrics
- Reliance on paired WSI-transcriptomic data from TCGA/CPTAC raises questions about generalizability to institutions without comprehensive datasets
- Clinical utility demonstration focuses on standard endpoints, potentially underestimating value for complex molecular classifications

## Confidence
- **High confidence**: Technical implementation of diffusion model, correlation metrics with real transcriptomic data, and statistical significance of performance improvements
- **Medium confidence**: Clinical interpretability claims require further validation for practical utility
- **Medium confidence**: Fairness claims across demographics are promising but based on limited demographic stratification in available datasets

## Next Checks
1. External validation on independent cancer cohorts from different institutions to assess model robustness and potential dataset-specific biases
2. Prospective clinical study comparing PathGen-guided molecular testing selection against standard clinical pathways to demonstrate actual healthcare impact
3. Multi-omics extension validation using orthogonal molecular data (proteomics, metabolomics) to establish broader utility beyond transcriptomics